| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $16.1M | +35.6% |
| SG&A Expense | $6.1M | +1.8% |
| Operating Income | -$22.2M | -24.3% |
| Net Income | -$20.8M | -30.2% |
| EPS (Basic) | -$1.93 | -31.3% |
| EPS (Diluted) | -$1.93 | -31.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $7.5M | -65.8% |
| Short-term Investments | $16.5M | -14.8% |
| Current Assets | $25.2M | -41.7% |
| Total Assets | $25.6M | -41.4% |
| Current Liabilities | $4.3M | +61.7% |
| Total Liabilities | $4.4M | +60.0% |
| Stockholders' Equity | $21.2M | -48.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$17.8M | -24.2% |
| Capital Expenditures | $13K | -32.8% |
| Investing Cash Flow | $3.4M | +462.2% |
| Financing Cash Flow | $67K | +113.3% |
| Free Cash Flow | -$17.8M | -24.1% |